Crockett Thomas Andrew 4
4 · KalVista Pharmaceuticals, Inc. · Filed Dec 28, 2023
Insider Transaction Report
Form 4
Crockett Thomas Andrew
DirectorPresident and CEO
Transactions
- Sale
Common Stock
2023-12-27$12.02/sh−30,000$360,453→ 127,532 total
Footnotes (2)
- [F1]The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 31, 2023.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.00 to $12.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.